A soluble form of endoglin (sEng) is known to be an extracellular domain of the full-length membrane endoglin, which is elevated during various pathological conditions related to vascular endothelium. In the current review, we tried to summarize a possible role of soluble endoglin in cardiovascular pathologies, focusing on its relation to endothelial dysfunction and cholesterol levels. We discussed sEng as a proposed biomarker of cardiovascular disease progression, cardiovascular disease treatment and endothelial dysfunction. We also addressed a potential interaction of sEng with TGF-β/eNOS or BMP-9 signaling. We suggest soluble endoglin levels to be monitored, because they reflect the progression/treatment efficacy of cardiovascular diseases related to endothelial dysfunction and hypercholesterolemia. A possible role of soluble endoglin as an inducer of endothelial dysfunction however remains to be elucidated.

Charles University Prague Faculty of Pharmacy in Hradec Kralove Department of Biological and Medical Sciences Heyrovskeho 1203 Hradec Kralove 500 05 Czech Republic

Citace poskytuje Crossref.org

Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration

Transgenic human C-reactive protein affects oxidative stress but not inflammation biomarkers in the aorta of spontaneously hypertensive rats

Prognostic value of soluble endoglin in patients with septic shock and severe COVID-19

Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

Long term effects of soluble endoglin and mild hypercholesterolemia in mice hearts

High soluble endoglin levels do not induce changes in structural parameters of mouse heart